The 19th Annual
Peptide Therapeutics

October 22-23, 2024
Scripps Seaside Forum

Registration Opens In July
2024 Symposium Sponsors

Board Members

Phil Dawson, Ph.D.

Professor of Chemistry, Scripps Research

Phil Dawson is a Professor in the Department of Chemistry, Scripps Research in La Jolla, CA and Dean of the Skaggs Graduate School of Chemical and Biological Sciences. He received an A.B. (1992) in Chemistry from Washington University, and Ph.D. (1996) from Scripps Research under the guidance of Steve Kent. After pursuing postdoctoral work at Caltech, he returned to Scripps as an Assistant Professor. He has served as President of the American Peptide Society, the Board of Directors for FASEB and co-chaired the 22nd American Peptide Symposium and the 2016 GRC. He has published over 180 papers, and has been honored with an Alfred P. Sloan Foundation fellowship, the Vincent du Vigneaud Award, the Max Bergmann Kreis Gold Medal, the Zervas Award and the RSC MedImmune Protein and Peptide Science Award and the Akabori Memorial Award. Professor Dawson is a pioneer of chemoselective ligation methods for macromolecule synthesis and modification and has applied these tools broadly to better understand biological systems.

Robert Hagopian

Director Business Development, Polypeptide

Mr. Robert A. Hagopian received his M.S. degree in Organic Chemistry from the University of California San Diego and his M.B.A from San Diego State University. His experience in peptide research and production spans over twenty five years which includes: Telios Pharmaceuticals (Manager, Peptide Production, 3 years) and NeoMPS, Inc. (Director, GMP Production 14 years). In his current position as Director of Business Development (13 years) at PolyPeptide, San Diego, Mr. Hagopian overseas the customer support activities for new and existing sales related to pre-clinical, clinical and commercial grade peptides.

Adrienne Day, Ph.D.

President, Blue Gum Advisors LLC

Dr. Day is the President of Blue Gum Advisors LLC, a consulting firm focused on providing business development support to the life science industry.  She is a seasoned business development professional with more than 30 years of experience in the biotechnology and biopharmaceutical industries. Dr. Day has hands-on operational and executive management experience in the non-profit, for-profit and startup environments.

Most recently she was Senior Director of Business Development for Ferring  Pharmaceuticals.  Prior to that Dr. Day ran a successful consulting practice. She has previously served as Vice President of Business Development at what is now the Sanford Burnham Prebys Medical Discovery Institute, Vice President of Business Development Conforma Therapeutics, Senior Director of Business Development at Molecumetics Ltd., Associate Director of Corporate Development at Ligand Pharmaceuticals. She was Ligand Pharmaceuticals’ first Project Manager, and began her biotechnology career at Invitrogen Corporation where she held various positions.

Dr. Day received her B.Sc., B.Sc. Honors, and Ph.D. degrees in Biochemistry from the University of Adelaide, Australia. She completed her postdoctoral training at the University of Southern California  and the La Jolla Cancer Research Center.

Philippe Pinton, PhD

SVP Global Head of Translational & Clinical Research & Development, Ferring Pharmaceuticals

Dr. Philippe Pinton is Senior Vice-President, Global Head of Clinical And Translational Sciences (CATS) at Ferring Pharmaceuticals. The CATS structure is a global integrated matrix from Discovery to late-stage Clinical Development to focus on severe unmet medical needs to deliver and sustain a portfolio of innovative medicines to help people live better lives.

Dr. Philippe Pinton has over 20 years’ experience in the Pharmaceutical Industry across Research & Development and Medical Affairs, in Asia, Europe and the USA, in major pharmaceutical companies, notably Eli Lilly & Company, Novartis and Takeda.

He received his MD., MSc., and PhD., degrees from the Universities of Lille and Paris, and his executive MBA from the HEC business school (France). Prior to joining the Pharmaceutical Industry, he was a resuscitation ward hospital practitioner.

His most recent works explored auto-immune or inflammatory diseases, infertility, and oncology, developing computational models integrating multiple omics and performing in silico clinical studies to better understand patients’ treatment response and related comorbidome.

Stefan Schunk, PhD

Senior Director, Medicinal Chemistry, Zealand Pharma

Stefan Schunk is Senior Director of Medicinal & Computational Chemistry at Zealand Pharma in Copenhagen, Denmark. He is leading the joint department to drive design and discovery of innovative peptide-based medicines, mainly focusing on metabolic and gastrointestinal diseases.

Prior to Zealand he spent 15 years at Grünenthal, a German specialty pharma, working in the fields of pain and inflammation. Here he served in various roles across research and early development – as External Innovation Lead scouting, evaluating, and in-licensing multiple research collaborations, as International Project Lead and heading the Medicinal Chemistry department. He started his Biotech career at Analyticon Discovery.

He performed postdoctoral work with Prof. Kocienski at Leeds University, UK in the field of natural product synthesis and received his Ph.D. in chemistry working for Prof. Enders at RWTH Aachen, Germany in the field of solid phase synthesis.

Antoine Henninot, PhD

Assoicate Director GI Chemistry, Takeda Pharmaceuticals

Dr. Henninot is the Associate Director of Chemistry at Takeda, San Diego, CA. He is leading discovery efforts in the peptide chemistry and bioconjugation group to generate novel peptide and oligonucleotide therapeutics that target gastrointestinal disease. Before joining Takeda, Dr. Henninot was the lead on multiple drug discovery projects and peptide chemistry efforts at the Ferring Research Institute, San Diego, CA. He obtained his M.Sc. at the Universite de Lille 1 in France and his Pharm.D. at the Universite de Lille 2. He stayed on to complete his Ph.D. in Medicinal Chemistry and Chemical Biology, under the supervision of Prof. Benoit Deprez and in collaboration with LFB Biotechnologie, working on identifying small molecule modulators of antibody post-translational modifications.


Click here to learn more about The Peptide Therapeutics Foundation or our Annual Peptide Therapeutics Symposium.